Albuferon

DRUG4 trials

Sponsors

Human Genome Sciences Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic Hepatitis CHCVHIV InfectionsHepatitis CHepatitis C, Chronic

Phase 1

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

CompletedNCT00489385

National Institute of Allergy and Infectious Diseases (NIAID)HCV, HIV Infections

Start: 2007-06-18End: 2011-03-15Updated: 2017-07-02

Phase 2

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

CompletedNCT00097435

Human Genome Sciences Inc.Hepatitis C

Start: 2004-10-31End: 2007-08-31Updated: 2013-08-02

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

CompletedNCT00115908

Human Genome Sciences Inc.Hepatitis C, Chronic

Start: 2005-05-31End: 2007-05-31Updated: 2013-11-07

A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3

CompletedNCT00656006

Human Genome Sciences Inc.Chronic Hepatitis C

Start: 2005-11-30End: 2007-04-30Updated: 2013-08-02